Tweet
<img alt="" height="1" width="1" />
Human Genome lung cancer drug fails to improve survival
Reuters
March 17 (Reuters) - Human Genome Sciences Inc (HGSI.O) said data from a mid-stage trial of its experimental lung cancer drug showed the drug did not improve progression-free survival or disease response, sending its shares down 2 percent before the ...
Human Genome drug falls short in midstage studyBusinessWeek
HGS investors shrug off a mid-stage cancer failureFierceBiotech
JP Morgan Maintains Human Genome Sciences (HGSI) Overweight RatingBenzinga
MSN Money -RTT News -MarketWatch (press release)
all 32 news articles »
More...